Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1Unknown 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 161Leukemia 99Lymphoma, Large B-Cell, Diffuse 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 91Leukemia, Myeloid, Acute 76Hodgkin Disease 73Lymphoma, Follicular 63Burkitt Lymphoma 60Lymphoma, Mantle-Cell 56Lymphoma, Large-Cell, Immunoblastic 55Small Cell Lung Carcinoma 46Leukemia, Lymphocytic, Chronic, B-Cell 42Lung Neoplasms 41Neuroblastoma 40Lymphoma, B-Cell, Marginal Zone 33Congenital Abnormalities 33Multiple Myeloma 30Recurrence 27Sarcoma 26Central Nervous System Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Myelodysplastic Syndromes 24Leukemia, Myelomonocytic, Acute 24Leukemia, Monocytic, Acute 24Leukemia, Erythroblastic, Acute 24Testicular Neoplasms 22Lymphoma, Large-Cell, Anaplastic 22Leukemia, Megakaryoblastic, Acute 22Brain Neoplasms 22

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2romidepsin 1prednylidene 1fludarabine phosphate 1fludarabine 1deltacortene 1Vorinostat 1Salvia hispanica seed extract 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1MLN 8237 1Lenalidomide 1Lactones 1Ki-1 Antigen 1Ifosfamide 1Diet, Gluten-Free 1Depsipeptides 1Carboplatin 1Bortezomib 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Enteropathy-Associated T-Cell Lymphoma × Etoposide × Clear all
NCT02561273 2023-12-13

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

University of Nebraska

Phase 1/2 Completed
54 enrolled 14 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Completed
22 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡